Abstract:Pancreatic ductal adenocarcinoma (PDA) is a highly lethal malignancy with a 5‐year survival rate of 6%, due in part to therapy resistance and late stage at diagnosis. A detailed understanding of the molecular alterations underlying this disease is required to uncover mechanisms of tumorigenesis and enable development of more effective therapies. We recently developed a novel 3D model system for culturing normal and diseased pancreatic tissue from both mice and humans. These pancreatic organoids can be passaged indefinitely in vitro , frozen, thawed, genetically manipulated and transplanted orthotopically into mice where they generate lesions faithfully reflecting their donor phenotype (normal, pre‐malignant, malignant). The ability to culture both normal and tumor‐derived cells in vitro under identical conditions has for the first time allowed a direct comparison of gene expression changes and response to therapeutic agents. We have used this new model to investigate tumor cell‐stroma interactions, screen drug libraries and model genetic alterations found in human tumors. G‐protein coupled receptors (GPRCs) transduce extracellular signals from a variety of ligands through the plasma membrane, resulting in the modulation of intracellular signaling pathways. This is accomplished in large measure by the activation of heterotrimeric G‐proteins and downstream second messengers. Composed of over 900 members in humans, GPCRs are seven‐transmembrane proteins that regulate many physiological processes including vision, olfaction, taste, behavior and autonomic nervous system transmission. This wide array of functions has resulted in the extensive utilization of GPCR targeted therapeutics, accounting for 30–50% of all currently used drugs. The wide use of GPCR drugs can also be attributed to GPCR localization on the cell surface, abrogating the requirement for a drug to be cell permeable, as well as the ability of GPCRs to bind a variety of ligands, including antibodies, peptides and small molecules. Furthermore, GPCR signaling can be tightly regulated through the utilization of agonists, antagonists and inverse agonists. However, drugs targeting GPCRs are rarely utilized in cancer treatment, despite evidence that GPCRs mediate many aspects of tumorigenesis, including cell proliferation, invasion, immune cell recruitment and secondary niche generation. Genomic analyses have uncovered GPCR mutations, copy number alterations and gene expression and methylation changes in a wide variety of cancers. We have utilized the organoid system to identify and characterize GPCRs upregulated in PDA. Furthermore, we have performed high throughout screens to identify GPCR‐targeted FDA approved drugs that specifically reduce proliferation in tumor‐derived organoids. As agonists and antagonists of GPCRs are currently used widely in the clinic, the identification of GPCRs as novel drivers of tumorigenesis may have immediate benefits for human cancer therapy.

Small-molecule targeting of GPCR-independent noncanonical G-protein signaling in cancer

Small Activating RNA Modulation of the G Protein‐Coupled Receptor for Cancer Treatment

Therapeutic effects of cell-permeant peptides that activate G proteins downstream of growth factors

In Silico Design of Novel RGS2-Galpha-q Interaction Inhibitors with Anticancer Activity

Small molecules targeting the innate immune cGAS‒STING‒TBK1 signaling pathway

Targeting Wnt signaling for improved glioma immunotherapy

Dual targeting of TIGIT and PD-1 with a novel small molecule for cancer immunotherapy

Structural basis for GPCR-independent activation of heterotrimeric Gi proteins

AGS3-based optogenetic GDI induces GPCR-independent Gβγ signaling and macrophage migration

Orphan G-protein coupled receptor GPCR-X as a novel cancer drug target: validation and mechanistic studies

A novel class of inhibitors that disrupts the stability of integrin heterodimers identified by CRISPR-tiling-instructed genetic screens

Pan-cancer in Silico Analysis of Somatic Mutations in G-protein Coupled Receptors: the Effect of Evolutionary Conservation and Natural Variance

Fragment Based Discovery of a Small Molecule RhoGDI2 Ligand HR3119 That Inhibits Cancer Cell Metastasis

Targeting G Protein–Coupled Receptors in Immuno-Oncological Therapies

Identification of Novel GANT61 Analogs with Activity in Hedgehog Functional Assays and GLI1-Dependent Cancer Cells

Preclinical assessment of galunisertib (LY2157299 monohydrate), a first-in-class transforming growth factor-β receptor type I inhibitor

Organoid models to interrogate GPCR regulation of pancreatic tumorigenesis

GABAergic signaling as a potential therapeutic target in cancers

Engineering cGAS-agonistic oligonucleotides as therapeutics for cancer immunotherapy

Structure-based design of CDC42 effector interaction inhibitors for the treatment of cancer

New insights into the molecular mechanisms of glutaminase C inhibitors in cancer cells using serial room temperature crystallography